###### Strengths and limitations of this study

-   We adopted the random effects model to analyse the pooled data to allow for a different effect in each population, and conducted stratified analysis to avoid heterogeneity.

-   This study was limited by some variables, such as age, gender, diet, living habits, environmental exposure and pathological type of patients.

-   This study was also limited by the small sample size in some subgroup analysis.

Introduction {#s1}
============

Fluorouracil (5-FU) is the backbone of treatments for gastric and oesophageal cancers. Oral fluoropyrimidines including capecitabine and tegafur show similar efficacy to 5-FU.[@R1] Fluoropyrimidine drugs themselves have no antitumour activity, but they are converted to 5-fluoro-dUMP, which can further form a ternary complex with 5, 10-methylene tetrahydrofolate (5, 10-MTHF) and thymidylate synthase (TS). Formation of this ternary complex results in sustained inhibition of TS; it prevents the conversion of 2′ -deoxyuridine-5′-monophosphate into 2′-deoxythymidine-5′-monophosphate, thereby restraining the synthesis of DNA.[@R5] This is considered as the predominant mechanism of the antitumour effect of fluoropyrimidines.

Folate metabolism is an important factor influencing the antitumour activity of fluoropyrimidines. Increased 5, 10-MTHF could produce tighter ternary complexes and improve the efficacy of fluoropyrimidine drugs. Methylenetetrahydrofolate reductase (MTHFR) is a critical enzyme in folate-metabolising pathway. It catalyses the irreversible conversion of 5, 10-MTHF to 5-methyltetrahydrofolate, and reduces the amount of 5, 10-MTHF available for binding to FdUMP and TS.[@R5] Therefore, MTHFR plays a key role in the anabolism of fluoropyrimidines to the active metabolites. *MTHFR* gene locates in chromosome 1p36.3, and is highly polymorphic.[@R7] Two common functional polymorphisms of *MTHFR*, C677T (rs1801133) and A1298C (rs1801131), have been identified, the main variants that could decrease the activity of MTHFR.[@R8] Thus, *MTHFR* C677T and A1298C polymorphisms may contribute greatly to the clinical response of fluoropyrimidine-based chemotherapy.

Theoretically, *MTHFR* gene polymorphisms are closely related to the efficacy of fluoropyrimidines for the treatment of gastric cancer and oesophageal cancer. However, the available evidence from the gene polymorphism studies in the clinic was weak, and the published results were inconsistent among studies.[@R10] Therefore, further assessment is needed. In this account, a systematic review and meta-analysis were carried out on the published data in order to comprehensively estimate the association of *MTHFR* C677T and A1298C polymorphisms with the clinical response to fluoropyrimidine-based chemotherapy in patients with oesophagogastric cancer.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

We conducted a comprehensive search of PubMed, Embase and Web of Science databases from inception up to October 2017 using a combination of the following terms: "methylenetetrahydrofolate reductase" or "MTHFR", "polymorphism" or "pharmacogenetic" or "genotype" or "variant", "fluoropyrimidine" or "fluorouracil" or "5-Fu" or "capecitabine" or "tegafur", and "gastric cancer" or "esophageal cancer" or "esophagogastric cancer". The search was limited to articles reported in English. We have included the full search strategy for PubMed as an example in the online [supplementary file](#SP1){ref-type="supplementary-material"}. To identify more potentially relevant studies, a manual search for references cited in the eligible articles was also performed.
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Selection criteria {#s2b}
------------------

The included literature in this study met the following criteria: (1) studies involving gastric cancer and oesophageal cancer; (2) chemotherapy regimens containing 5-FU, capecitabine or tegafur; (3) studies using validated molecular methods for genotyping and (4) studies providing information on *MTHFR* polymorphism or estimated genetic effects on response to treatment. No restrictions were imposed on the design of the studies, which could have been prospective or retrospective studies. Studies investigating susceptibility, progression or severity, and the case reports, letters, conference abstracts, meta-analysis and reviews were excluded.

Data extraction {#s2c}
---------------

The data were independently extracted by two researchers (LZ and QF). For each included study, the following information was collected: first author, publication year, ethnicity of the study population, study design, distribution of gender and age in patients, cancer type, chemotherapy regimen, clinical response, genotype distribution of *MTHFR* and genotyping methods, and the Hardy-Weinberg equilibrium examination result. Any discrepancies in data extraction were resolved by consensus.

Assessment of study quality {#s2d}
---------------------------

The quality of the included studies was evaluated independently by two reviewers according to the Newcastle-Ottawa Scale (NOS). The NOS includes three parameters of quality for studies: selection of the study population, comparability of subjects and exposure assessment, with scores ranging from 0 to 9. NOS scores of 0--4 and 5--9 were considered as low-quality and high-quality studies, respectively.

Statistical analysis {#s2e}
--------------------

The OR and corresponding 95% CI were used to assess the strength of the association between *MTHFR* C677T and A1298C polymorphisms and clinical response. Three genetic models including the allele model (C677T: T vs C; A1298C: C vs A), dominant model (C677T: CT +TT vs CC; A1298C: AC +CC vs AA) and recessive model (C677T: TT vs CC +CT; A1298C: CC vs AA +AC) were compared. The pooled OR and 95% CIs were assessed by the random effects model. The heterogeneity among studies was evaluated by the Q-test. P\<0.1 was considered significant heterogeneity. I^2^ statistic was also calculated to quantify the heterogeneity: I^2^ \<25%, I^2^=25%--50%, I^2^=50%--75% and I^2^ \>75%, indicated no heterogeneity, moderate heterogeneity, large heterogeneity and extreme heterogeneity, respectively. Subgroup analysis was carried out based on cancer type (gastric cancer and oesophageal cancer), ethnicity (Caucasians and Asians) and study design (prospective and retrospective). The sensitivity analysis was performed by the sequential omission of individual studies to assess the stability of the results. The publication bias was detected using Begg-Mazumdar adjusted rank correlation test and Egger's regression test. All statistical analyses were conducted with the software STATA V.12.0.

Results {#s3}
=======

Characteristics of the included studies {#s3a}
---------------------------------------

As shown in [figure 1](#F1){ref-type="fig"}, a total of 113 relevant publications were retrieved from the databases. According to the inclusion/exclusion criteria, data from 12 studies that investigated the association between the *MTHFR* C677T and A1298C polymorphisms and response to fluoropyrimidine-based chemotherapy in oesophagogastric cancer were collected for the meta-analysis.[@R12] The eligible studies were published between 2006 and 2017, and sample sizes ranged from 52 to 369 ([table 1](#T1){ref-type="table"}). Among these publications, four studies (33.3%) were conducted prospectively; nine studies were in Caucasians, and three in Asians; seven were reports on gastric cancer, four on oesophageal cancer and one on oesophagogastric cancer ([table 1](#T1){ref-type="table"}). In the studies, responders were defined as patients with complete response, partial response or no recurrence, and non-responders were defined as patients with stable disease, progressive disease or early recurrence. Of the eligible studies, 12 reports including 2020 patients reported tumour response events associated with *MTHFR* C677T polymorphism, and 5 studies provided 1183 patients for testing the association of *MTHFR* A1298C variant with response to chemotherapy ([table 1](#T1){ref-type="table"}). The quality of each eligible article was assessed by the NOS, and all studies received a high NOS score (≥5, data not shown).

![Flow diagram of study selection.](bmjopen-2017-020767f01){#F1}

###### 

Characteristics of the studies included in the meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (year)                       Ethnicity   Clinical data gathering   Patients, n (male%)   Age, mean (range)   Cancer type                        Chemotherapy regimens   Definition of responders   Definition of non- responders   MTHFR SNP                   Method of MTHFR SNP analysis          Hardy-Weinberg equilibrium reported and in equilibrium?
  ---------------------------------- ----------- ------------------------- --------------------- ------------------- ---------------------------------- ----------------------- -------------------------- ------------------------------- --------------------------- ------------------------------------- ---------------------------------------------------------
  Ott *et al*[@R12] (2006)           Caucasian   Retrospective             135 (71.8)            56 (23--70)         Advanced GC                        PLF, E-PLF,\            CR, PR                     SD, PD                          C677T                       TaqMan assay                          Not reported
                                                                                                                                                        paclitaxel-PLF                                                                                                                                       

  Sarbia *et al*[@R13] (2006)        Caucasian   Retrospective             68 (−)                \_                  Oesophageal squamous cell cancer   FLEP                    CR, PR                     SD, PD                          C677T                       PCR-HRM                               Not reported

  Goekkurt *et al*[@R14] (2006)      Caucasian   Retrospective             52 (65.4)             56 (27--82)         Advanced GC                        5-FU+\                  CR, PR                     SD, PD                          C677T                       PCR-RFLP                              Not reported
                                                                                                                                                        cisplatin+FA                                                                                                                                         

  Ruzzo *et al*[@R15] (2006)         Caucasian   Prospective               175 (56.6)            61 (38--79)         Advanced GC                        Fluorouracil/\          CR, PR                     SD, PD                          C677T                       PCR-RFLP                              Not reported
                                                                                                                                                        cisplatin                                                                                                                                            

  Wu *et al*[@R16] (2006)            Caucasian   Retrospective             210 (86.67)           61 (32--79)         Oesophageal cancer                 Fu+cisplatin+\          No recurrence              Recurrence                      C677T A1298C                TaqMan assay                          Not reported
                                                                                                                                                        paclitaxel                                                                                                                                           

  Goekkurt *et al*[@R17] (2009)      Caucasian   Prospective               134 (68.6)            64 (27--86)         Advanced GC                        FLO, FLP                CR, PR                     SD, PD                          C677T A1298C                PCR-RFLP                              Yes

  Chen *et al*[@R18] (2010)          Asian       Retrospective             98 (70.4)             \_                  Oesophageal squamous cell cancer   Cisplatin/\             CR, PR                     SD, PD                          C677T                       Sequencing                            Yes
                                                                                                                                                        fluorouracil                                                                                                                                         

  Zhang *et al*[@R19] (2014)         Asian       Retrospective             362 (77.3)            57.5 (18--82)       GC                                 F, FP, FT, TPF,\        CR, PR                     SD, PD                          C677T A1298C rs2274976 GA   MALDI-TOF-MS                          Yes
                                                                                                                                                        EOF and others                                                                                                                                       

  Blank *et al*[@R20] (2014)         Caucasian   Retrospective             369 (83.7)            \_                  Oesophagogastric cancer            OLF/PLF,\               CR, PR                     SD, PD                          C677T A1298C                PCR-based KASP genotyping chemistry   Yes
                                                                                                                                                        EOX, FLOT                                                                                                                                            

  Liu *et al*[@R21] (2016)           Asian       Retrospective             108 (59.2)            \_                  mGC                                EOF                     CR, PR                     SD, PD                          C677T A1298C                TaqMan assay                          Yes

  Meulendijks *et al*[@R22] (2017)   Caucasian   Prospective               185 (73)              59 (27--77)         Advanced GC                        Cisplatin+\             CR, PR                     SD, PD                          C677T                       Sequencing/PCR-RFLP                   Yes
                                                                                                                                                        capecitabine                                                                                                                                         

  Gusella *et al*[@R23] (2017)       Caucasian   Prospective               124 (83.9)            60 (42--74)         Advanced oesophageal cancer        Fluorouracil+\          No recurrence              Recurrence                      C677T                       PCR-RFLP                              Yes
                                                                                                                                                        docetaxel+\                                                                                                                                          
                                                                                                                                                        cisplatin                                                                                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-FU, 5-fluorouracil; CR, complete response; EOF, 5-FU/capecitabine/S-1+cisplatin/oxaliplatin+epirubicin; EOX, epirubicin+oxaliplatin+capecitabin; E-PLF, epirubicin+cisplatin+leucovorin+5-FU; F, 5-FU/capecitabine/S-1; FA, folinic acid; FLEP, 5-FU+folinic acid+etoposide+cisplatin; FLP, 5-FU+leucovorin+cisplatin;FLO, 5-FU+leucovorin+oxaliplatin; FP, 5-FU/capecitabine/S-1+c isplatin/oxaliplatin; FT, 5-FU/capecitabine/S-1+d ocetaxel/paclitaxel; FLOT, 5-fluoruracil+folinic acid+oxaliplatin+docetaxel; GC, gastric cancer; HRM, High Resolution Melting; KASP, a competitive allele-specific PCR genotyping system; MALDI-TOF-MS, matrixassisted laser desorption/ionization time-of-flight mass spectrometry; MGC, metastatic gastric cancer; MTHFR, methylenetetrahydrofolate reductase; OLF, oxaliplatin/cisplatin+folinic acid+fluorouracil; PD, progressive disease; PR, partial response; PLF, cisplatin+leucovorin+5-FU; RFLP, restriction fragment length polymorphism; TPF, 5-FU/capecitabine/S-1+c isplatin/oxaliplatin+docetaxel/paclitaxel; SD, stable disease; SNP, single nucleotide polymorphisms.

Meta-analysis results {#s3b}
---------------------

The main results of meta-analysis and heterogeneity test for *MTHFR* C677T were summarised in [table 2](#T2){ref-type="table"}. No significant correlation was found between *MTHFR* C677T polymorphism and response to fluoropyrimidine-based chemotherapy in all of the three genetic models: allele model (OR 0.93, 95% CI 0.76 to 1.15) ([figure 2A](#F2){ref-type="fig"}), dominant model (OR 0.94, 95% CI 0.72 to 1.23) (online [supplementary figure S1A](#SP2){ref-type="supplementary-material"}) and recessive model (OR 1.02, 95% CI 0.74 to 1.39) (online [supplementary figure S1B](#SP2){ref-type="supplementary-material"}). The results of Q-test and I^2^ statistic indicated moderate heterogeneity in allele and dominant models (P~Q~ \>0.1, 25% \< I^2^\<50%), and no significant heterogeneity under the recessive model (P~Q~=0.356, I^2^=9.4%).
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![Forest plot. (A) Forest plot for the allele contrast of methylenetetrahydrofolate reductase (*MTHFR*) C677T variant and response to fluoropyrimidine-based chemotherapy; (B) Forest plot for the allele contrast of *MTHFR* A1298C variant and response to fluoropyrimidine-based chemotherapy.](bmjopen-2017-020767f02){#F2}

###### 

OR with the corresponding 95% CI, heterogeneity results, Begg' test and Egger' test for genetic contrasts of methylenetetrahydrofolate reductase C677T

  -----------------------------------------------------------------------------------------------------------------------------------
  Models            Population   No studies            Random effects OR (95% CI)   P values\   I^2^ (%)   Begg' test   Egger' test
                                                                                    (Q-test)                            
  ----------------- ------------ --------------------- ---------------------------- ----------- ---------- ------------ -------------
  T versus C        All          9                     0.93 (0.76 to 1.15)          0.109       38.9       0.251        0.355

  GC                6            0.85 (0.61 to 1.17)   0.058                        53.3        0.452      0.495        

  EC                2            1.00 (0.66 to 1.53)   0.226                        31.7        1.000      --           

  Caucasians        7            0.99 (0.78 to 1.25)   0.167                        34.2        0.548      0.404        

  Asians            2            0.72 (0.37 to 1.41)   0.081                        67.1        1.000      --           

  Prospective       3            1.06 (0.74 to 1.51)   0.185                        40.7        1.000      0.711        

  Retrospective     6            0.86 (0.65 to 1.14)   0.105                        45.1        0.452      0.190        

  Dominant model    All          11                    0.94 (0.72 to 1.23)          0.131       33.4       0.533        0.836

  GC                6            0.75 (0.46 to 1.22)   0.043                        56.4        1.000      0.835        

  EC                4            1.15 (0.78 to 1.71)   0.878                        0.0         1.000      0.939        

  Caucasians        8            1.02 (0.76 to 1.37)   0.278                        19.2        0.108      0.400        

  Asians            3            0.78 (0.39 to 1.52)   0.097                        57.1        1.000      0.862        

  Prospective       3            1.31 (0.84 to 2.04)   0.442                        0.0         0.296      0.231        

  Retrospective     8            0.83 (0.61 to 1.14)   0.155                        34.2        0.902      0.588        

  Recessive model   All          10                    1.02 (0.74 to 1.39)          0.356       9.4        1.000        0.929

  GC                7            1.05 (0.75 to 1.47)   0.454                        0.0         0.764      0.944        

  EC                2            0.93 (0.21 to 4.19)   0.047                        74.6        1.000      --           

  Caucasians        8            0.98 (0.67 to 1.44)   0.368                        8.1         0.386      0.408        

  Asians            2            0.95 (0.39 to 2.29)   0.147                        52.5        1.000      --           

  Prospective       4            0.87 (0.56 to 1.36)   0.405                        0.0         0.734      0.768        

  Retrospective     6            1.12 (0.71 to 1.77)   0.298                        17.8        1.000      0.924        
  -----------------------------------------------------------------------------------------------------------------------------------

EC, oesophageal cancer; GC, gastric cancer.

In the stratified analysis by cancer type, seven studies were used to evaluate the association of *MTHFR* C677T polymorphism with response to fluoropyrimidine-based chemotherapy in gastric cancer, and four studies in oesophageal cancer. As shown in [table 2](#T2){ref-type="table"}, no significant association was observed in both gastric and oesophageal cancer under all genetic models. The similar results were obtained in the stratified analysis according to ethnicity or study design. The association was still not significantly altered between *MTHFR* C677T polymorphism and response to fluoropyrimidine-based chemotherapy in all subgroups ([table 2](#T2){ref-type="table"}).

For the association between *MTHFR* A1298C polymorphism and response to fluoropyrimidine-based chemotherapy, the pooled results indicated no significant association in all genetic models ([table 3](#T3){ref-type="table"}, [figure 2B](#F2){ref-type="fig"}, and online [supplementary figure S1C,D](#SP2){ref-type="supplementary-material"}). Large heterogeneity was observed in allele and dominant contrasts (P~Q~ \<0.1, I^2^ \>50%; [table 3](#T3){ref-type="table"}). Moreover, as indicated in [table 3](#T3){ref-type="table"}, when stratified by cancer type, ethnicity or study design, there was no significant association in all subgroups.

###### 

OR with the corresponding 95% CI, heterogeneity results, Begg' test and Egger' test for genetic contrasts of methylenetetrahydrofolate reductase A1298C

  -----------------------------------------------------------------------------------------------------------------------------------
  Models            Population   No studies            Random effects OR (95% CI)   P values\   I^2^ (%)   Begg' test   Egger' test
                                                                                    (Q-test)                            
  ----------------- ------------ --------------------- ---------------------------- ----------- ---------- ------------ -------------
  C versus A        All          5                     0.88 (0.56 to 1.40)          0.002       76.0       0.806        0.501

  GC                3            0.72 (0.36 to 1.44)   0.022                        73.7        0.296      0.070        

  EC                1                                                                                                   

  Caucasians        3            0.98 (0.69 to 1.40)   0.162                        45.1        1.000      0.958        

  Asians            2            0.84 (0.21 to 3.40)   0.007                        86.5        1.000      --           

  Prospective       1                                                                                                   

  Retrospective     4            0.96 (0.54 to 1.70)   0.001                        81.1        0.308      0.464        

  Dominant model    All          5                     0.80 (0.47 to 1.35)          0.007       71.8       0.462        0.332

  GC                3            0.63 (0.30 to 1.35)   0.038                        69.5        0.296      0.310        

  EC                1                                                                                                   

  Caucasians        3            0.86 (0.50 to 1.45)   0.091                        58.4        1.000      0.854        

  Asians            2            0.83 (0.19 to 3.63)   0.011                        84.4        1.000      --           

  Prospective       1                                                                                                   

  Retrospective     4            0.92 (0.50 to 1.69)   0.007                        75.5        0.308      0.218        

  Recessive model   All          5                     1.15 (0.50 to 2.67)          0.207       32.2       0.462        0.516

  GC                3            0.71 (0.14 to 3.59)   0.138                        49.5        1.000      0.955        

  EC                1                                                                                                   

  Caucasians        3            1.40 (0.74 to 2.64)   0.489                        0.0         0.296      0.290        

  Asians            2            0.43 (0.03 to 5.73)   0.146                        52.6        1.000      --           

  Prospective       1                                                                                                   

  Retrospective     4            1.08 (0.31 to 3.79)   0.120                        48.6        0.308      0.606        
  -----------------------------------------------------------------------------------------------------------------------------------

EC, oesophageal cancer; GC, gastric cancer.

Sensitivity analysis {#s3c}
--------------------

The influence of any single study on the overall results was analysed by gradual deletion of individual studies. As shown in [figure 3A,B](#F3){ref-type="fig"} and online [supplementary figure S2A--D](#SP3){ref-type="supplementary-material"}, no significant difference was observed when any of the studies was excluded in all of the three genetic models, indicating the reliability and stability of the results.
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![Sensitivity analysis. (A) Sensitivity analysis for the allele contrast of *MTHFR* C677T polymorphism. (B) Sensitivity analysis for the allele contrast of *MTHFR* A1298C polymorphism.](bmjopen-2017-020767f03){#F3}

Publication bias {#s3d}
----------------

The Egger's regression test and Begg's test were performed to evaluate the publication bias. As shown in [figure 4A,B](#F4){ref-type="fig"} and online [supplementary figure S3A--S3D](#SP4){ref-type="supplementary-material"}, the shape of the funnel plot was symmetrical, and the p values were all greater than 0.05 in both Begg's test and Egger's test under all genetic models ([tables 2 and 3](#T2){ref-type="table"}), suggesting the absence of significant publication bias in the overall meta-analysis.
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![Publication bias. (A) Begg's funnel plot of the publication bias in the allele model of *MTHFR* C677T polymorphism. (B) Begg's funnel plot of the publication bias in the allele model of *MTHFR* A1298C polymorphism.](bmjopen-2017-020767f04){#F4}

Discussion {#s4}
==========

There are many factors influencing the chemosensitivity to fluoropyrimidine drugs; among them, the polymorphism of metabolism-related genes of fluoropyrimidine is one of the most pivotal factors.[@R24] Despite the biological rationale suggesting a role of *MTHFR* polymorphisms in affecting the efficacy of fluoropyrimidines, the results of genetic polymorphism studies related to the response to fluoropyrimidine-based chemotherapy in patients with gastric and oesophageal cancer are still conflicting. Zhang *et al* has conducted a retrospective comparative exploratory study on *MTHFR* polymorphisms in gastric cancer, and concluded that the homozygous genotypes rs2274976G/G and rs1801131A/A were over-represented in responsive patients; carriers of the rs2274976A allele genotypes (G/A and A/A) and of the rs1801131C allele genotypes (A/C and C/C) were prevalent in non-responsive patients.[@R19] These results suggested that polymorphisms of the *MTHFR* gene could be used as predictors for the response to fluorouracil-based chemotherapy in gastric cancer. However, the studies performed by several other research groups in oesophagogastric cancer found no significant correlation between them.[@R22] To further comprehensively evaluate the effect of *MTHFR* C677T and A1298C polymorphisms on fluoropyrimidine-based chemotherapy in patients with oesophagogastric cancer, a meta-analysis including 12 studies was performed. The results of pooled data suggested that there was no significant association between *MTHFR* C677T and A1298C polymorphism and the clinical response to fluoropyrimidine-based chemotherapy in sufferers with gastric and oesophageal cancer under all three genetic models. In the subgroup analysis based on cancer type, ethnicity or study design, the correlation was still not detected. This result was similar to the meta-analysis performed by Zintzaras *et al* in colorectal cancer, in which it showed that *MTHFR* C677T and A1298C gene polymorphisms could not be considered as reliable predictors of response to fluorouracil chemotherapy in patients with colorectal cancer.[@R28]

Several potential limitations of the present meta-analysis should be acknowledged. First, this study was based on the reported data of the eligible study without adjustment for other covariates such as age and gender, which may result in relatively low power to estimate the real association. This is also a general problem of meta-analysis when pooling data from primary studies.[@R29] Second, the treatment of oesophagogastric cancer could also be influenced by diet, living habits, environmental exposure and pathological type of patients, while these factors were not considered in this study. Third, some stratified analysis in this account was not sufficiently large (contain only two studies). Therefore, the association in the relevant subgroup analysis was unconvincing, and needed to be further estimated. Finally, heterogeneity was a noticeable problem in this meta-analysis, and we found moderate or large heterogeneity in most of the comparison. Potential sources of heterogeneity were not found by the sensitivity analysis. When stratified by cancer type, ethnicity and study design, the heterogeneity just greatly decreased in partial subgroups ([tables 2 and 3](#T2){ref-type="table"}).

Multiple factors may contribute to the heterogeneity in this study. Treatment setting may be one the most pivotal influence factors. The eligible studies covered all stages of management in oesophagogastric cancer, including neoadjuvant (preoperative), adjuvant (postoperative) and palliative therapy. Meanwhile, in the chemotherapy regimens, fluoropyrimidines were all combined with other agents. The difference in treatment type and combination regimen may cause the diversities in efficacy, thus contributing to the heterogeneity among studies. Folate intake status is also a factor influencing the efficacy of fluoropyrimidine drugs.[@R31] MTHFR is a critical enzyme in folate-metabolising pathway, and folate status may affect the association of *MTHFR* polymorphisms with response to fluoropyrimidine-based treatment through gene--nutrition interaction. However, this effect cannot be assessed unless specifically sought and accounted for in the individual studies. In addition, the administration mode of fluoropyrimidines may also be one of the causes of heterogeneity. Fluoropyrimidines act in two different ways (bolus/infusion administration). Bolus fluoropyrimidines may incorporate into RNA and preclude protein synthesis, whereas continuous infusion exerts its major effect on TS.[@R33] The eligible studies in this meta-analysis used both modes of fluorouracil administration.

Conclusion {#s5}
==========

In summary, we demonstrate that *MTHFR* C677T and A1298C polymorphisms cannot be considered as reliable factors for predicting the clinical response to fluoropyrimidine-based chemotherapy in patients with oesophagogastric cancer. However, the results in present meta-analysis should be interpreted cautiously due to the existence of heterogeneity. Therefore, well-designed prospective studies based on larger sample sizes are warranted to validate the present findings. Additionally, in view of the fact that fluoropyrimidines exert their effects through a multistep, multigenic cascade, hence, composite pharmacogenomics analysis may be more precise for efficacy prediction of fluoropyrimidine-based regimens.
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